Caffeine
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1948
- First approval year
- 1948
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Caffeine
- Molecular weight
- 194.19
- Structure (SMILES)
- Cn1c(=O)c2c(ncn2C)n(C)c1=O
- caffeine component of anoquan
- Caffeine component of anoquan
- caffeine component of cafergot
- Caffeine component of cafergot
- caffeine component of darvon compound
- Caffeine component of darvon compound
- caffeine component of dhc plus
- Caffeine component of dhc plus
- caffeine component of esgic
- Caffeine component of esgic
- caffeine component of excedrin
- Caffeine component of excedrin
- caffeine component of femcet
- Caffeine component of femcet
- caffeine component of fioricet
- Caffeine component of fioricet
- caffeine component of fiorinal
- Caffeine component of fiorinal
- caffeine component of invagesic
- Caffeine component of invagesic
- caffeine component of invagesic forte
- Caffeine component of invagesic forte
- caffeine component of lanorinal
- Caffeine component of lanorinal
- caffeine component of medigesic plus
And 27 more, listed on the interactive page.
- acetaminophen 250 mg isopropylantipyrine 150 mg and anhydrous caffeine 50 mg
- anhydrous caffeine
- Anhydrous caffeine
- Anhydrous caffeine (120mg)
- Anhydrous caffeine (45mg)
- ANHYDROUS CAFFEINE [JAN]
- anhydrous caffeine 120mg
- anhydrous caffeine 45mg
- anhydrous caffeine jan
- anoquan component caffeine
- ANOQUAN COMPONENT CAFFEINE
- cafergot component caffeine
- CAFERGOT COMPONENT CAFFEINE
- caffeine
- Caffeine
- CAFFEINE [EP MONOGRAPH]
- CAFFEINE [FCC]
- CAFFEINE [FHFI]
- CAFFEINE [HSDB]
- CAFFEINE [IARC]
- CAFFEINE [II]
- CAFFEINE [MART.]
- CAFFEINE [MI]
- CAFFEINE [ORANGE BOOK]
- CAFFEINE [USP MONOGRAPH]
And 101 more, listed on the interactive page.
- CAS registry numbers
- 58-08-2
- ChEMBL ID
- CHEMBL113
- InChIKey
- RYYVLZVUVIJVGH-UHFFFAOYSA-N
- PubChem compound IDs
- 2519
- FDA ingredient codes (UNII)
- 3G6A5W338E
- D11AX26
- N06BC01
Sources for recorded values
- 1886
- 142218
- Applicant
- ACTAVIS LABS UT INC
- Approval date
- 30 Jul 1992
- Application number
- NDA020232
- Status
- Authorised
- Status date
- 2 Jul 2009
- Authorisation date
- 2 Jul 2009
- Approved indications
- Treatment of primary apnoea of premature newborns.
- Product number
- EMEA/H/C/001014
- Authorisation holder
- Chiesi Farmaceutici SpA
- Priority medicines scheme
- No
- Generic
- No
- Biosimilar
- No
- Generic medicines
- 0
- Biosimilar medicines
- 0
- Advanced therapy
- No
- Conditional approval
- No
- Additional monitoring
- No
- Accelerated assessment
- No
- Exceptional circumstances
- No
Therapeutic areas
- Apnea
European medicines record
- Patents
- 34
- Designations
- 1
- Earliest recorded loss of exclusivity
- 2 Aug 2044
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Over the counter
- United States (FDA)
- Approved
- European Union (EMA)
- Authorised
- Pharmacology name
- caffeine
- Type
- Natural product
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Oral
- Parenteral
- topical
- Action
- Activator
- Action type
- ACTIVATOR
- Target
- RyR1
- Gene symbol
- RYR1
- Protein identifier
- P21817
- Action
- Activator
- Action type
- ACTIVATOR
- Target
- RyR3
- Gene symbol
- RYR3
- Protein identifier
- Q15413
- Action
- Activator
- Action type
- ACTIVATOR
- Target
- RyR2
- Gene symbol
- RYR2
- Protein identifier
- Q92736
- Action
- Antagonist
- Action type
- Antagonist
- Target
- A3 receptor
- Gene symbol
- ADORA3
- Protein identifier
- P0DMS8
- Median affinity
- 4.88
- Affinity units
- pKi
- Primary target
- Yes
- Action
- Antagonist
- Action type
- Antagonist
- Target
- A2A receptor
- Gene symbol
- ADORA2A
- Protein identifier
- P29274
- Affinity units
- pKi
- Primary target
- Yes
- Action
- Antagonist
- Action type
- Antagonist
- Target
- A2B receptor
- Gene symbol
- ADORA2B
- Protein identifier
- P29275
- Affinity units
- pKi
- Primary target
- Yes
- Action
- Antagonist
- Action type
- Antagonist
- Target
- A1 receptor
- Gene symbol
- ADORA1
- Protein identifier
- P30542
- Affinity units
- pKi
- Primary target
- Yes
- Action
- Antagonist
- Action type
- Antagonist
- Target
- IP3R1
- Gene symbol
- ITPR1
- Protein identifier
- Q14643
- Mechanism
- Adenosine receptor antagonist
- Action type
- Antagonist
- Target
- Adenosine receptor
- Protein identifier
- P0DMS8
- Mechanism
- Adenosine receptor antagonist
- Action type
- Antagonist
- Target
- Adenosine receptor
- Protein identifier
- P29274
- Mechanism
- Adenosine receptor antagonist
- Action type
- Antagonist
- Target
- Adenosine receptor
- Protein identifier
- P29275
- Mechanism
- Adenosine receptor antagonist
- Action type
- Antagonist
- Target
- Adenosine receptor
- Protein identifier
- P30542
Open Targets mechanisms
- Mechanism
- Adenosine receptor antagonist
- Action type
- Antagonist
- Target
- Adenosine receptor
- Action type
- Antagonist
- Gene symbol
- ADORA3
- Protein identifier
- P0DMS8
- Organism
- Homo sapiens
- Target development level
- Chemical evidence
- Action type
- Antagonist
- Gene symbol
- ADORA2A
- Protein identifier
- P29274
- Organism
- Homo sapiens
- Target development level
- Clinical
- Action type
- Antagonist
- Gene symbol
- ADORA2B
- Protein identifier
- P29275
- Organism
- Homo sapiens
- Target development level
- Clinical
- Action type
- Antagonist
- Gene symbol
- ADORA1
- Protein identifier
- P30542
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Dermatitis, Atopic
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000274
- Subject identifier
- D003876
- Condition
- Atrial Fibrillation
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000275
- Subject identifier
- D001281
- Condition
- Breast Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000305
- Subject identifier
- D001943
- Condition
- Crohn Disease
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000384
- Subject identifier
- D003424
- Condition
- Neoplasms
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Psoriasis
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000676
- Subject identifier
- D011565
- Condition
- Arthritis, Rheumatoid
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000685
- Subject identifier
- D001172
- Condition
- Colitis, Ulcerative
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000729
- Subject identifier
- D003093
- Condition
- Melanoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000756
- Subject identifier
- D008545
- Condition
- HIV Infections
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000764
- Subject identifier
- D015658
- Condition
- Obesity
- Highest recorded phase
- 3
- Condition identifier
- EFO:0001073
- Subject identifier
- D009765
- Condition
- Coronary Disease
- Highest recorded phase
- 3
- Condition identifier
- EFO:0001645
- Subject identifier
- D003327
- Condition
- Cocaine-Related Disorders
- Highest recorded phase
- 2
- Condition identifier
- EFO:0002610
- Subject identifier
- D019970
- Condition
- Melanoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0002617
- Subject identifier
- D008545
- Condition
- Pain
- Highest recorded phase
- 4
- Condition identifier
- EFO:0003843
- Subject identifier
- D010146
- Condition
- Intermittent Claudication
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003876
- Subject identifier
- D007383
- Condition
- Attention Deficit Disorder with Hyperactivity
- Highest recorded phase
- 4
- Condition identifier
- EFO:0003888
- Subject identifier
- D001289
- Condition
- Multiple Sclerosis, Relapsing-Remitting
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003929
- Subject identifier
- D020529
- Condition
- Hepatitis C, Chronic
- Highest recorded phase
- 1
- Condition identifier
- EFO:0004220
- Subject identifier
- D019698
- Condition
- Anemia
- Highest recorded phase
- 1
- Condition identifier
- EFO:0004272
- Subject identifier
- D000740
- Condition
- Sexual Dysfunction, Physiological
- Highest recorded phase
- 1
- Condition identifier
- EFO:0004714
- Subject identifier
- D012735
- Condition
- Hypotension, Orthostatic
- Highest recorded phase
- 1
- Condition identifier
- EFO:0005252
- Subject identifier
- D007024
- Condition
- Communicable Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0005741
- Subject identifier
- D003141
- Condition
- Common Cold
- Highest recorded phase
- 3
- Condition identifier
- EFO:0007214
- Subject identifier
- D003139
- Condition
- Hypoxia
- Highest recorded phase
- 3
- Condition identifier
- EFO:0009444
- Subject identifier
- D000860
And 30 more, listed on the interactive page.
- Condition identifier
- EFO_0000275
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000305
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000537
- Condition identifier
- EFO_0000612
- Condition identifier
- EFO_0000616
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000756
- Highest recorded phase
- 1
- Condition identifier
- EFO_0001073
- Highest recorded phase
- 3
- Condition identifier
- EFO_0001645
- Highest recorded phase
- 3
- Condition identifier
- EFO_0002610
- Condition identifier
- EFO_0003876
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003888
- Condition identifier
- EFO_0003890
- Condition identifier
- EFO_0003925
- Condition identifier
- EFO_0003926
- Highest recorded phase
- 1
- Condition identifier
- EFO_0004272
- Highest recorded phase
- 1
- Condition identifier
- EFO_0004335
- Highest recorded phase
- 2
- Condition identifier
- EFO_0004352
- Condition identifier
- EFO_0004714
- Highest recorded phase
- 1
- Condition identifier
- EFO_0004888
- Condition identifier
- EFO_0005252
- Condition identifier
- EFO_0005422
- Highest recorded phase
- 1
- Condition identifier
- EFO_0006834
- Highest recorded phase
- 1
- Condition identifier
- EFO_0007214
- Highest recorded phase
- 3
- Condition identifier
- EFO_0009444
- Highest recorded phase
- 2
- Condition identifier
- EFO_0009444
- Highest recorded phase
- 3
And 62 more, listed on the interactive page.
- Event
- abdominal pain upper
- Reports
- 62
- Reporting signal score
- 39.8398
- Event
- balance disorder
- Reports
- 92
- Reporting signal score
- 156.915
- Event
- blood calcium decreased
- Reports
- 80
- Reporting signal score
- 245.718
- Event
- cognitive disorder
- Reports
- 99
- Reporting signal score
- 212.782
- Event
- constipation
- Reports
- 119
- Reporting signal score
- 123.828
- Event
- creatinine renal clearance decreased
- Reports
- 80
- Reporting signal score
- 295.687
- Event
- depressed level of consciousness
- Reports
- 98
- Reporting signal score
- 192.465
- Event
- dermatitis contact
- Reports
- 19
- Reporting signal score
- 34.3099
- Event
- drug abuse
- Reports
- 55
- Reporting signal score
- 64.3897
- Event
- drug dependence
- Reports
- 41
- Reporting signal score
- 65.5546
- Event
- drug hypersensitivity
- Reports
- 110
- Reporting signal score
- 65.9623
- Event
- ductus arteriosus stenosis foetal
- Reports
- 7
- Reporting signal score
- 25.9522
- Event
- dyspepsia
- Reports
- 38
- Reporting signal score
- 34.4709
- Event
- electrocardiogram qt prolonged
- Reports
- 31
- Reporting signal score
- 27.0079
- Event
- emphysema
- Reports
- 24
- Reporting signal score
- 61.236
- Event
- fall
- Reports
- 114
- Reporting signal score
- 62.4408
- Event
- gastric ulcer
- Reports
- 24
- Reporting signal score
- 35.6635
- Event
- headache
- Reports
- 133
- Reporting signal score
- 42.2783
- Event
- hypertension neonatal
- Reports
- 6
- Reporting signal score
- 30.5527
- Event
- hypertrichosis
- Reports
- 81
- Reporting signal score
- 391.878
- Event
- hypoaesthesia
- Reports
- 48
- Reporting signal score
- 27.9693
- Event
- hypokalaemia
- Reports
- 42
- Reporting signal score
- 42.4287
- Event
- hypotension
- Reports
- 113
- Reporting signal score
- 81.6363
- Event
- metabolic acidosis
- Reports
- 53
- Reporting signal score
- 88.4792
- Event
- migraine
- Reports
- 36
- Reporting signal score
- 30.0833
And 15 more, listed on the interactive page.
- NCT00223691
- NCT00302289
- NCT00377975
- NCT02048215
- NCT05445232
- NCT00388128
- NCT00432887
- NCT04504045
- NCT00437632
- NCT00443170
- NCT00459420
- NCT01190735
- NCT01738178
- NCT03970798
- NCT00471952
- NCT00495092
- NCT00733993
- NCT00513110
- NCT00564824
- NCT00692510
- NCT00726726
- NCT04570085
- NCT00930306
- NCT01001299
- NCT01080677
And 60 more, listed on the interactive page.
- Dose
- 1-2 tablets
- Route
- Oral
- How often
- Every 4 hours as needed
Conditions of use
- Total daily dosage should not exceed 6 tablets
- Hydrogen bond acceptors
- 6
- Hydrogen bond donors
- 0
- Polar surface area
- 61.82
- Calculated partition coefficient (ALogP)
- -1.03
- Calculated partition coefficient (XLogP)
- -0.1
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 0
- Heavy atoms
- 14
- Molecular formula
- C8H10N4O2
- Monoisotopic mass
- 194.08037557
- Natural product
- Yes
- 0054-0650
- 0054-3000
- 0517-2502
- 0527-1552
- 0527-1695
- 0527-4094
- 0527-4095
- 0591-2640
- 0591-2641
- 0591-3220
- 0591-3369
- 0713-0166
- 0781-2270
- 0904-6938
- 10702-253
- 11534-187
- 13107-075
- 13925-535
- 13925-536
- 24470-917
- 42291-181
- 43547-686
- 46672-053
- 50268-553
- 50991-999
And 73 more, listed on the interactive page.
- Recorded assays
- 6,907
- Active assays
- 157
- Confirmatory
- Other
- Summary
- Central Nervous System Stimulants
- Phosphodiesterase Inhibitors
- Purinergic P1 Receptor Antagonists
These details could not be displayed.
Related records
Trials (210)
- "Pecos" B-adrenergic and PPAR-G Stimulation Upregulates Lipid Metabolism in Human Subcutaneous Fat
- A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors
- A Dental Pain Study Comparing The Analgesic Efficacy Of Ibuprofen/Caffeine
- A Drug Interaction Study of KW-6356 With Midazolam, Caffeine, or Rosuvastatin
- A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants
- A Placebo-controlled Study to Investigate the Safety, and Pharmacokinetics of Oral GSK626616AC in Healthy Subjects
- A Possible Therapeutic Role for Adenosine During Inflammation
- A Single-Dose Study to Investigate the Pharmacokinetics of MK-7655 in Participants With Impaired Renal Function (MK-7655-005)
- A Study Evaluating the Potential of BMS-984923 to Alter the Systemic Exposure of Three Orally Administered Probe Substrates
- A Study of Caffeine on Cardiac Arrhythmias
- A Study of Effect of Multiple Doses of LOXO-305 on the Pharmacokinetics of Single Oral Doses of CYP1A2, CYP2C9, CYP2C19 Substrates in Healthy Participants
- A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis
- A Study of LY4515100 in Healthy Participants
- A Study to Assess Effect of JNJ-54861911 on Pharmacokinetics of Cocktail Representatives for Cytochrome P450 (CYP) 3A4, CYP2B6, CYP2C9, and CYP1A2 Substrates
- A Study to Assess the Effect of BMS-986419 on the Single Dose Drug Levels of Probe Substrates in Healthy Participants
- A Study to Compare How Different Substances (Caffeine, Warfarin, Omeprazole, Metoprolol, and Midazolam) Are Handled by the Body of Healthy People and People With Liver Cirrhosis
- A Study to Determine if Caffeine Accelerates Emergence From Anesthesia
- A Study to Determine if Caffeine Accelerates Emergence From Propofol Anesthesia
- A Study to Estimate the Effect of Multiple Dose Abrocitinib on Caffeine, Efavirenz, and Omeprazole in Healthy Participants
- A Study to Evaluate How Daily Dosing With Enzalutamide Affects the Metabolism of Caffeine and Dextromethorphan in Men With Prostate Cancer
Approved for (3)
- Attention deficit-hyperactivity disorder
- Drug dependence
- Migraine disorder
In development for (48)
- Acute myeloid leukemia Phase 1
- Alcohol dependence Phase 1
- Alzheimer disease Phase 3
- Amblyopia Phase 1
- Amyotrophic lateral sclerosis Phase 1
- Anemia Phase 1
- Atopic eczema Phase 1
- Atrial fibrillation Phase 3
- Brain injury Phase 2
- Breast cancer Phase 2
- Breast carcinoma Phase 2
- Bronchopulmonary dysplasia Phase 3
- Chronic hepatitis C virus infection Phase 1
- Cocaine dependence Phase 2
- Common cold Phase 3
- Coronary artery disorder Phase 3
- COVID-19 Phase 1
- Crohn disease Phase 1
- Diabetic kidney disease Phase 2
- Dysmenorrhea Phase 3
Other linked conditions (6)
- Burning mouth syndrome
- Hypertensive disorder
- Mood disorder
- Myocardial infarction
- Obsessive-compulsive disorder
- Schizophrenia